The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Prime Medicine Inc (NASDAQ: PRME) was $5.61 for the day, up 3.31% from the previous closing price of $5.43. In other words, the price has increased by $3.31 from its previous closing price. On the day, 0.52 million shares were traded. PRME stock price reached its highest trading level at $5.92 during the session, while it also had its lowest trading level at $5.32.
Ratios:
Our analysis of PRME’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.91 and its Current Ratio is at 8.91. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on May 20, 2024, initiated with a Buy rating and assigned the stock a target price of $10.
On May 16, 2024, Citigroup Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $10.
On April 22, 2024, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $17.Chardan Capital Markets initiated its Buy rating on April 22, 2024, with a $17 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 15 ’24 when ARCH Venture Partners XII, LLC bought 3,200,000 shares for $6.25 per share. The transaction valued at 20,000,000 led to the insider holds 3,200,000 shares of the business.
ARCH Venture Partners X, LLC bought 3,200,000 shares of PRME for $20,000,000 on Feb 15 ’24. The 10% Owner now owns 3,200,000 shares after completing the transaction at $6.25 per share. On Feb 15 ’24, another insider, NELSEN ROBERT, who serves as the Director of the company, bought 3,200,000 shares for $6.25 each. As a result, the insider paid 20,000,000 and bolstered with 3,200,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRME now has a Market Capitalization of 690736896 and an Enterprise Value of 460911840. For the stock, the TTM Price-to-Sale (P/S) ratio is 1141.30 while its Price-to-Book (P/B) ratio in mrq is 2.76. Its current Enterprise Value per Revenue stands at 779.885 whereas that against EBITDA is -2.367.
Stock Price History:
Over the past 52 weeks, PRME has reached a high of $15.75, while it has fallen to a 52-week low of $4.11. The 50-Day Moving Average of the stock is -9.97%, while the 200-Day Moving Average is calculated to be -18.66%.
Shares Statistics:
PRME traded an average of 902.93K shares per day over the past three months and 550960 shares per day over the past ten days. A total of 97.38M shares are outstanding, with a floating share count of 50.59M. Insiders hold about 57.85% of the company’s shares, while institutions hold 37.46% stake in the company. Shares short for PRME as of 1721001600 were 13716264 with a Short Ratio of 15.19, compared to 1718323200 on 11569740. Therefore, it implies a Short% of Shares Outstanding of 13716264 and a Short% of Float of 24.01.
